Regulation 57 not applicable: no non-convertible securities with interest, dividend or principal payable for the quarter
The company has informed BSE that Regulation 57 of SEBI (LODR) Regulations, 2015 does not apply to it for the quarter/half year ended 30.09.2026.
- Period covered
- quarter/half year ended 30.09.2026
- Regulation 57 applicability
- does not apply to it for the quarter/half year ended 30.09.2026
- Reason stated
- no non-convertible securities on which interest, dividend or principal is payable during the quarter
- Signed by
- Dr K Koteswara Rao, Chairman & Managing Director
What the update says
Transgene Biotek has written to BSE regarding compliance with Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter/half year ended 30.09.2026.
The letter states that Regulation 57 is not applicable to the company since there are no non-convertible securities for which interest, dividend or principal is payable during the quarter. The company has requested the exchange to take this on record.
What Regulation 57 relates to
Regulation 57 applies to listed entities that have issued non-convertible securities such as debentures or bonds.
- Such entities are required to give periodic confirmations to the exchange on payment of interest, dividend and principal on those securities.
- Where no such securities are outstanding for which a payment falls due in the period, the entity states that the regulation does not apply to it for that period.
What this communication is
The letter is a periodic compliance intimation about whether a specific disclosure requirement applies to the company for the stated period.
- It is addressed to the General Manager, Department of Corporate Services, BSE Limited.
- It is signed by Dr K Koteswara Rao, Chairman & Managing Director.
- The subject line identifies it as compliance under Regulation 57 for the quarter/half year ended 30.09.2026.
How a retail investor can read it
- This is an intimation about applicability of a rule to the company for the period.
- It is not an order win, an earnings release or a fund-raising announcement.
- On its own, it does not change how the company's operations are described in the letter.
In short, the update is a rule-applicability statement made to the exchange for the quarter/half year ended 30.09.2026, and the company has asked for it to be taken on record.
Also from Transgene Biotek
Board meeting on 10 October 2026 to consider appointing Eswara Rao & Co. as statutory auditors
2 Oct 2026
ROC grants three-month extension for holding 36th AGM, now due by December 31, 2026
25 Sep 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.